NxTAG SARS-CoV-2 test was designed to detect SARS-CoV-2 virus, which causes coronavirus. Credit: Fusion Medical Animation / Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Biotechnology company Luminex has received the US Food and Drug Administration’s (FDA) emergency use authorisation (EUA) for its NxTAG CoV Extended Panel test intended to detect SARS-CoV-2 virus that causes Covid-19.

High-complexity molecular laboratories will be able to diagnose up to 96 patients in almost four hours with the NxTAG test on the company’s compact MAGPIX System that uses bead-based chemistry.

Furthermore, the test can be run in parallel with the NxTAG Respiratory Pathogen Panel (RPP) to deliver a complete picture of a patient’s respiratory health.

Luminex president and CEO Nachum Shamir said: “We are partnering with our customers at clinical laboratories to address the global pandemic, providing fast, reliable, scalable, multiplexed tests that can help stem the spread of Covid-19 disease, while also ensuring that our tests are cost-effective.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“While there are many companies providing tests that can detect the SARS-CoV-2 strain, to our knowledge, Luminex is the only company providing tests that can detect and differentiate between SARS-CoV-2 and the other common respiratory infections, while keeping the price below government reimbursement levels to make testing more affordable for our customers and the healthcare system.”

Currently, the company is supporting laboratories in the US, Asia, and Europe with the testing. It has scaled up the manufacturing capacity to produce up to 300,000 NxTAG tests a month.

Earlier this week, the Biomedical Advanced Research and Development Authority (BARDA) granted $642K in funding to Luminex to develop and validate the NxTAG SARS-CoV-2 test.

Meanwhile, the US is witnessing an increase in coronavirus cases and related deaths. According to the latest reports, the death toll has reached 2,513, while the number of confirmed cases stands at 143,055.